- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.04. | How will AI shape the future of the NHS? | ||
| 01.04. | Large pharma drug licensing from China hits high at 28% in 2024 | ||
| 01.04. | Pfizer's RSV vaccine wins expanded approval in EU, gaining edge over GSK | ||
| 01.04. | NHS England abolished: a bold cure or a risky operation? | ||
| 01.04. | Apollomics and LaunXP agree on NSCLC treatment in Asia | ||
| 01.04. | FDA approves AstraZeneca's Imfinzi combo for bladder cancer | ||
| 01.04. | Pharmaceutical Technology Excellence Awards 2025: NorthWest EHealth | ||
| 01.04. | ACC 2025: Imbria's ninerafaxstat data shows potential for cardiometabolic HFpEF | ||
| 31.03. | Cell and gene therapy collections: The need for consistency | ||
| 31.03. | Sanofi's Qfitlia approved by FDA as first haemophilia therapy for all patients | ||
| 31.03. | Biopharma IPOs showed signs of recovery in 2024 | ||
| 31.03. | Vertex halts development of diabetes cell therapy after trial failure | ||
| 31.03. | Saving shelved ultra-rare therapies through unorthodox funding | ||
| 31.03. | ACC 25: Oral semaglutide reduces cardiovascular events in T2D patients | ||
| 28.03. | Novo Nordisk strikes $1bn deal for Lexicon's oral obesity drug | ||
| 28.03. | Macau approves IASO Bio's multiple myeloma therapy | ||
| 28.03. | MSD's subcutaneous Keytruda non-inferior to IV version of blockbuster drug | ||
| 28.03. | Weill Cancer Hub East launches to transform treatment | ||
| 28.03. | Genmab's Tivdak approved in Japan for advanced cervical cancer | ||
| 27.03. | Soleno wins FDA approval for Prader-Willi hyperphagia treatment | ||
| 27.03. | HHS announces major workforce cuts and reorganisation | ||
| 27.03. | How bioconjugation is unlocking the next generation of drug development | ||
| 27.03. | Ionis and Sobi agree on olezarsen commercialisation | ||
| 27.03. | Blockbuster potential drugs ruled the 2024 pipeline with 53% rise over 2023 | ||
| 27.03. | AGA overhauls UC treatment pathway: early, high-efficacy therapies now preferred |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
